Anhydrous Polymorph A2 of Compound A for Ocular Formulation Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing pharmaceutical formulations of Compound A, a selective adenosine A1 receptor agonist, face challenges with variability in particle growth size and stability, which affects its physical and chemical properties, solubility, and formulation handling characteristics, necessitating the discovery of stable polymorphic forms for effective intraocular pressure treatment.
Innovation Solution
The development of anhydrous polymorph A2 of Compound A, characterized by specific crystal data and methods of preparation, including heating in a liquid vehicle to achieve at least 75% purity, micronization, and formulation with surfactants and preservatives for enhanced stability and ophthalmic administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing pharmaceutical formulations of Compound A are used, then the drug can be administered for treating elevated intra-ocular pressure, but the formulations exhibit variability in particle growth size and stability, affecting physical and chemical properties
Solution Approach 1:
The patent applies parameter changes by identifying and characterizing different polymorphic forms of Compound A, each with distinct crystal structures and physical properties. By selecting specific polymorphic forms (anhydrous forms A1 and A2) with defined crystal parameters, the invention achieves consistent particle characteristics and improved stability, resolving the variability issue in existing formulations
Solution Approach 2:
The invention utilizes phase transitions between different polymorphic forms of Compound A. The patent describes methods to control and achieve specific polymorphic forms through controlled crystallization and phase transition processes, ensuring consistent particle growth and enhanced stability in the final pharmaceutical formulation
2Adaptability or versatility
If different polymorphic forms of Compound A are used, then formulation properties can be controlled, but the physical and solid state chemical properties vary between polymorphs
Solution Approach 1:
The patent applies local quality by characterizing specific regions or aspects of each polymorphic form's properties. The invention identifies distinct crystal structures, melting points, and solubility characteristics for each polymorphic form (A1 and A2), allowing selective use of specific property profiles depending on formulation requirements while maintaining compositional stability within each form
3Ease of manufacture
If Compound A is prepared using existing procedures, then the compound can be synthesized, but the product may contain mixtures of polymorphic forms requiring additional purification
Solution Approach 1:
The patent applies preliminary action by incorporating specific crystallization conditions and polymorph selection steps directly into the synthesis procedure. The invention describes methods to obtain the desired polymorphic form (A1 or A2) as the primary or sole product during the crystallization step, eliminating the need for subsequent polymorph purification and simplifying the overall manufacturing process
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The anhydrous polymorph A2 form provides improved stability, solubility, and handling characteristics, ensuring consistent drug delivery and prolonged stability in ocular formulations, effectively reducing intraocular pressure.
Implementation Method 1
heating in a liquid vehicle to achieve at least 75% purity
Implementation Method 2
The development of anhydrous polymorph A2 of Compound A, characterized by specific crystal data
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention provides novel anhydrous polymorph forms of 2R,3S,4R,5R)-5-(6-(cyclopentylamino)-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl nitrate (Compound A). The present invention also provides processes for preparation of the anhydrous polymorphic forms of compound A.